Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
Raphael Mohr(Charité - Universitätsmedizin Berlin), Christoph Roderburg(Düsseldorf University Hospital), Burcin Özdirik(Charité - Universitätsmedizin Berlin), Sven H. Loosen(Düsseldorf University Hospital), Tom Luedde(Düsseldorf University Hospital), Joeri Lambrecht(Vrije Universiteit Brussel), Fabian Jost‐Brinkmann(Charité - Universitätsmedizin Berlin), Frank Tacke(Charité - Universitätsmedizin Berlin), Münevver Demir(Charité - Universitätsmedizin Berlin), Linda Hammerich(Charité - Universitätsmedizin Berlin)
Cited by 33
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k